Mylan, a generic form of current #MS treatment dimethyl fumarate, given favourable court ruling in the US. bit.ly/2Ao5aCg. Visit neuro-compass.education/ for up to date expert-led #MS content!

New survey finds majority of people with #MS use complementary and alternative medicine. bit.ly/2NN8vxO. Visit neuro-compass.education/ for up to date expert-led #MS content!

Neurological disability, age and obesity found to be risk factors for severe COVID-19 in #MS patients, but not DMT exposure. bit.ly/3eRlx9c. Visit neuro-compass.education/ for up to date expert-led #MS content!

Hookworm trial shows evidence of immune system regulation and potential benefit for #MS patients. bit.ly/2ViLLJZ. Visit neuro-compass.education/ for up to date expert-led #MS content!

Serum NfL levels may be predictive of long-term clinical outcomes in #MS. go.nature.com/3i5pw4d. Visit neuro-compass.education/ for up to date expert-led #MS content!

Enrolment begins for Phase I trial of potential new relapsing #MS treatment, SAR442168. bit.ly/2Z9Ysbr. Visit neuro-compass.education/ for up to date expert-led #MS content!

Changes in UK COVID-19 advice announced for those shielding, which may include some #MS patients. bit.ly/3dBlzAP. Visit neuro-compass.education/ for up to date expert-led #MS content!

US and UK #MS patients at increased risk of depression compared with non-MS patients. bit.ly/2ZbeRfD. Visit neuro-compass.education/ for up to date expert-led #MS content!

Switching from natalizumab to another #MS DMT may increase risk of relapse. bit.ly/31gCDtn. Visit neuro-compass.education/ for up to date expert-led #MS content!

FDA extends review process for potential new #MS drug ofatumumab by 3 months. reut.rs/2zRKN07. Visit neuro-compass.education/ for up to date expert-led #MS content!

Fatigue, sleep disturbance and pain may be first signs of #MS. bit.ly/2zRJsX9. Visit neuro-compass.education/ for up to date expert-led #MS content!

Lipid mediator profiles predict response to therapy with an oral frankincense extract in relapsing-remitting #MS. go.nature.com/2MbIxmI. Visit neuro-compass.education/ for up to date expert-led #MS content!

People living in urban areas are 30% more likely to develop #MS than those living in rural areas. bit.ly/2TPWaw1. Visit neuro-compass.education/ for up to date expert-led #MS content!

Potential new #MS drug ofatumumab shows a good efficacy and safety profile in latest data from phase III trials. bit.ly/36G3Ru4. Visit Neuro-Compass for up to date expert-led #MS content!

Specific cognitive rehabilitation shown to have real-world benefit on cognitive functioning in #MS. bit.ly/3ezoMBV. Visit Neuro-Compass for up to date expert-led #MS content!

EMA approves reduced infusion time for #MS patients taking ocrelizumab. bit.ly/2M7qZbq. Visit neuro-compass.education/ for up to date expert-led #MS content!

A new study of people with #MS in England shows they are at increased risk of cardiovascular disease. bit.ly/36IcRyS. Visit Neuro-Compass for up to date expert-led #MS content!

Higher levels of blood NfL associated with the risk of worse #MS disability over time. bit.ly/36S00KJ. Visit neuro-compass.education/ for up to date expert-led #MS content!

European Commission approves ozanimod for the treatment of adults with active relapsing-remitting #MS. bit.ly/3dr0zO5. Visit neuro-compass.education/ for up to date expert-led #MS content!

Increases in disability reduced by long-term fingolimod use for secondary progressive #MS patients. bit.ly/3fKmMrZ. Visit neuro-compass.education/ for up to date expert-led #MS content!